Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gyre Therapeutics, Inc. - Common Stock (NQ: GYRE )

11.90 -0.30 (-2.46%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,606
Open 12.20
Bid (Size) 11.00 (1)
Ask (Size) 12.20 (1)
Prev. Close 12.20
Today's Range 11.76 - 12.22
52wk Range 8.260 - 30.39
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
From Gyre Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-49.98%
-49.98%
1 Month
+2.32%
+2.32%
3 Month
-13.08%
-13.08%
6 Month
+19.96%
+19.96%
1 Year
-55.38%
-55.38%

More News

Read More
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024
Via InvestorPlace
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q1 2024
Via InvestorPlace
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Via Benzinga
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
From Gyre Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.